Triphase Accelerator Corporation Announces Positive Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma TORONTO and SAN DIEGO, June 04, 2016 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept,...

Triphase Accelerator Corporation Announces Expansion of Collaboration with Celgene in the Development of Marizomib for the Treatment of Gliomas TORONTO and SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept,...

Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma TORONTO and SAN DIEGO, April 19, 2016 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2...

Triphase Accelerator Corporation Announces Positive Preclinical Results for CBZed-Nano™ in Docetaxel-Resistant Prostate Cancer Models TORONTO and SAN DIEGO, April 18, 2016 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2...